Who Owns IQVIA Company?

IQVIA Bundle

Get Bundle
Get Full Bundle:
$15 $10
$15 $10
$15 $10
$15 $10
$15 $10
$15 $10

TOTAL:

Who Really Owns IQVIA?

Ever wondered who pulls the strings at one of the biggest players in healthcare intelligence and clinical research? Understanding IQVIA SWOT Analysis is just the start; knowing its ownership structure is key to grasping its strategic moves and market influence. This deep dive into the IQVIA company ownership will reveal the key players shaping its future.

Who Owns IQVIA Company?

IQVIA's journey, from the 2016 merger of Quintiles and IMS Health to its current status as a Fortune 500 company, is a testament to its strategic evolution. As a publicly traded entity, understanding who owns IQVIA, including its major shareholders and the IQVIA parent company, is crucial for investors and anyone tracking the healthcare sector. We'll explore the IQVIA stock and the impact of its investors on its business model and future direction, providing insights into the latest news about IQVIA ownership.

Who Founded IQVIA?

The current entity, IQVIA, emerged from a merger, combining IMS Health and Quintiles. Understanding the origins of these companies is key to grasping the evolution of IQVIA's ownership. This section delves into the founders and early ownership structures of the two companies that formed the basis of the current IQVIA company.

IMS Health, later known as IMS Health, was founded in New York City in 1954 by Bill Frohlich and David Dubow. Quintiles Transnational, on the other hand, was established in 1982 in Chapel Hill, North Carolina, by Dennis Gillings. These two companies, each with its unique history and ownership structure, eventually merged to create the IQVIA we know today.

While specific equity details from the inception of IMS Health and Quintiles are not readily available, the companies' financial journeys provide insights into their ownership evolution. Quintiles went public in 1994, and IMS Health underwent several ownership changes, including being taken private and later returning to the public market.

Icon

IMS Health Origins

Founded in 1954 in New York City by Bill Frohlich and David Dubow.

Icon

Quintiles Foundation

Established in 1982 in Chapel Hill, North Carolina, by Dennis Gillings.

Icon

Early Focus

IMS Health focused on pharmaceutical market intelligence.

Icon

Quintiles' Initial Focus

Quintiles provided biostatistical consulting services to pharmaceutical companies.

Icon

Public Market Entry

Quintiles had an IPO in 1994.

Icon

IMS Health's Evolution

IMS Health was spun off from Dun & Bradstreet.

Icon

Key Ownership Events

The ownership of both IMS Health and Quintiles evolved significantly over time, influencing the IQVIA ownership structure. IMS Health was acquired by TPG Capital, Canada Pension Plan Investment Board, and Leonard Green & Partners in late 2009 for $5.2 billion. Quintiles went private in 2003 through a management buyout valued at $1.7 billion. Both companies later re-entered the public market, reflecting changes in IQVIA's parent company landscape. For more information on the competitive landscape, you can refer to Competitors Landscape of IQVIA.

  • IMS Health was taken private in late 2009 for $5.2 billion.
  • Quintiles went private in 2003 via a $1.7 billion management buyout.
  • IMS Health went public again in April 2014.
  • Quintiles returned to the public market in 2013 with a valuation of approximately $5 billion.

IQVIA SWOT Analysis

  • Complete SWOT Breakdown
  • Fully Customizable
  • Editable in Excel & Word
  • Professional Formatting
  • Investor-Ready Format
Get Related Template

How Has IQVIA’s Ownership Changed Over Time?

The most significant shift in the ownership structure of the IQVIA company occurred in May 2016. This was when Quintiles and IMS Health merged in an all-stock deal. IMS Health shareholders received 0.384 shares of Quintiles common stock for each of their IMS Health shares. This resulted in an ownership split, with IMS Health shareholders owning 51.4% and Quintiles shareholders holding 48.6% of the combined entity. Initially, the merged company was known as QuintilesIMS, but it was later rebranded as IQVIA in November 2017.

As of early 2025, the IQVIA parent company, IQVIA Holdings Inc., is publicly traded on the New York Stock Exchange (NYSE). Its ownership is largely held by institutional investors. These entities reflect a high level of confidence in the company's future prospects. Understanding who owns IQVIA provides insight into the company's financial stability and strategic direction.

Shareholder Shares Held (as of March 31, 2025) Approximate Percentage
Vanguard Group Inc. 19,838,315 Not Specified
BlackRock, Inc. 14,777,928 Not Specified
Harris Associates L.P. 11,169,383 Not Specified
State Street Corp 7,723,208 Not Specified

In May 2025, institutional investors collectively held approximately 90.45% of IQVIA's shares. Mutual funds held around 101.02%, a figure that can be influenced by short positions or other complex investment strategies. Insider ownership, which includes shares held by company executives and directors, was approximately 0.47% in May 2025. The remaining shares are held by individual retail investors and smaller entities. The IQVIA investors include a diverse group of financial entities.

Icon

Key Ownership Facts

IQVIA is a publicly traded company, primarily owned by institutional investors.

  • The Vanguard Group Inc. and BlackRock, Inc. are among the largest shareholders.
  • Institutional investors hold a significant majority of the shares.
  • Insider ownership is a small percentage of the total shares.
  • The merger of Quintiles and IMS Health was a pivotal event in the company's ownership history.

IQVIA PESTLE Analysis

  • Covers All 6 PESTLE Categories
  • No Research Needed – Save Hours of Work
  • Built by Experts, Trusted by Consultants
  • Instant Download, Ready to Use
  • 100% Editable, Fully Customizable
Get Related Template

Who Sits on IQVIA’s Board?

The current board of directors significantly influences the governance of the IQVIA company. The Nominating and Governance Committee is responsible for identifying and reviewing potential candidates for the board. As of February 2025, the board emphasizes diversity, with 56% of director nominees being women and/or racially or ethnically diverse. All directors, except the chairman, are independent, and all board committees are independent as well.

Directors are elected annually, and in uncontested elections, a majority vote determines the outcome. If an incumbent director doesn't receive a majority vote, they are expected to offer their resignation to the Board. This structure ensures accountability and responsiveness to shareholder interests within the IQVIA ownership framework.

Board Member Title Independent
Ari Bousbib Chairman and CEO No
Michael J. Kassan Lead Independent Director Yes
Linda Sanford Director Yes

IQVIA's voting structure is straightforward, with a single class of voting stock. Each common stock holder is entitled to one vote per share. Stockholders have the right to proxy access and can call special meetings. The company also has established share ownership guidelines for both directors and key executives. There have been no recent proxy battles or significant activist investor campaigns publicly reported, which provides stability in the IQVIA parent company's decision-making processes as of early 2025.

Icon

Understanding IQVIA's Governance

The board of directors oversees IQVIA's operations, ensuring independent oversight and accountability. The company has a clear voting structure, giving each shareholder one vote per share. This structure helps maintain a transparent and responsive governance model for IQVIA investors.

  • Independent directors ensure unbiased oversight.
  • Annual elections promote accountability.
  • Shareholder rights, including proxy access, are protected.
  • No recent proxy battles indicate stability.

IQVIA Business Model Canvas

  • Complete 9-Block Business Model Canvas
  • Effortlessly Communicate Your Business Strategy
  • Investor-Ready BMC Format
  • 100% Editable and Customizable
  • Clear and Structured Layout
Get Related Template

What Recent Changes Have Shaped IQVIA’s Ownership Landscape?

Over the past few years, the IQVIA company has focused on returning value to its shareholders, primarily through share repurchase programs. In 2024, the company bought back $1.35 billion of its common stock. As of December 31, 2024, there was $1.013 billion remaining for share repurchases. This authorization was increased by an additional $2.0 billion on February 5, 2025, bringing the total remaining authorization to $3.013 billion. For the quarter ending March 31, 2025, share buybacks totaled $375 million, indicating a continued commitment to this strategy.

The company's commitment to shareholder value is further reflected in its financial performance and future outlook. IQVIA reaffirmed its full-year 2025 guidance, expecting revenue growth at constant currency ex-COVID of 4% to 7%. The company anticipates an Adjusted EBITDA margin expansion of up to 20 basis points and Adjusted Diluted Earnings per Share growth of 5% to 9%. Furthermore, acquisitions are expected to contribute an additional 100-150 basis points to revenue growth. The company does not currently plan to pay cash dividends on common stock.

In terms of industry trends, IQVIA continues to invest in technology enhancements, including its CORE data platform and Orchestrated Customer Engagement (OCE) suite, incorporating more AI and machine learning capabilities. The company is expanding its use of real-world evidence to support regulatory submissions and market access. While the biopharma sector saw a slowdown in mergers and acquisitions in 2024, with a focus on smaller transactions, the potential for increased M&A activity remains, especially with big pharma's estimated deal capacity exceeding $1.5 trillion in 2025.

Icon Share Repurchases

IQVIA has been actively repurchasing its shares to return value to shareholders. In 2024, the company repurchased $1.35 billion of its common stock. The company increased its share repurchase authorization by $2.0 billion on February 5, 2025, showing ongoing commitment.

Icon Financial Outlook

IQVIA expects revenue growth of 4% to 7% in 2025, excluding COVID-19 impacts. The company anticipates Adjusted EBITDA margin expansion and growth in Adjusted Diluted Earnings per Share. Acquisitions are expected to add to revenue growth.

Icon Industry Trends

IQVIA is investing in technology, including AI and machine learning. The company is expanding the use of real-world evidence. The biopharma sector shows a focus on smaller M&A deals, but big pharma has significant deal capacity.

Icon Ownership Structure

IQVIA is a publicly traded company. The company's focus on share repurchases indicates a strategic approach to managing its capital structure. Information on major shareholders can be found in public filings.

IQVIA Porter's Five Forces Analysis

  • Covers All 5 Competitive Forces in Detail
  • Structured for Consultants, Students, and Founders
  • 100% Editable in Microsoft Word & Excel
  • Instant Digital Download – Use Immediately
  • Compatible with Mac & PC – Fully Unlocked
Get Related Template

Related Blogs

Data Sources

Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.